Will Bupa Arabia and Tawuniya and MedGulf and AXA Cooperative cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Ajovy is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by SFDA?

The SFDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; SFDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Saudi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Saudi Commission for Health Specialties (SCFHS) and the SFDA verifies the active license; the SFDA application records both the prescribing physician and the dispensing facility.

Can I receive Ajovy at home?

The dispensing facility must be Saudi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 630 to 700 per month (or ~$2,100 per 3-month dose). Delivered quote within 24h.Get my quote

Ajovy access in Saudi Arabia: the SFDA named-patient pathway

How patients in the Kingdom of Saudi Arabia legally obtain Ajovy (fremanezumab-vfrm) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Saudi Arabia access Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults through the SFDA named-patient pathway, a Saudi Food and Drug Authority-administered mechanism that allows a Saudi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in SAR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Ajovy reaches patients in Saudi Arabia

Ajovy (fremanezumab-vfrm, a humanised IgG2-delta-kappa monoclonal antibody that selectively binds calcitonin gene-related peptide ligand isoforms from Teva Pharmaceuticals) received US FDA approval in September 2018 for the preventive treatment of migraine in adults, with the dosing options of 225 mg subcutaneously once monthly or 675 mg (three consecutive 225 mg injections) subcutaneously every three months per the FDA label at accessdata.fda.gov/scripts/cder/daf. The Saudi Food and Drug Authority registered-drug list at sfda.gov.sa/en/drugs-list includes fremanezumab under Teva's Saudi commercial arrangement; specific pen and pre-filled syringe presentation availability across the kingdom can be intermittent, and the once-monthly versus quarterly schedule selected by the prescriber may not be locally stocked. Where the locally stocked presentation does not match the prescription or the patient was previously stabilised on the US-sourced product, Saudi patients access the drug through the SFDA Personal Importation of Medicines pathway under the Conditions and Requirements for the Clearance or Personal Export of Pharmaceutical Products at sfda.gov.sa Drug-6567E, or for hospital-led cases through the SFDA Special Access Programme for unregistered drugs. The treating Saudi-licensed neurologist issues a medical report (approved by the treatment institution and dated within 6 months prior to submission per the SFDA Drug-6567E hard requirement) documenting the chronic migraine or episodic migraine diagnosis with monthly migraine days, prior preventive-therapy exposure (topiramate, propranolol, amitriptyline, candesartan, onabotulinum toxin A for chronic migraine), the rationale referencing the HALO trials at clinicaltrials.gov, and the planned monthly or quarterly schedule. SFDA does not publish a fixed processing-time SLA; SFDA electronic services target same-day to several-working-day turnaround when documentation is complete.

Where Ajovy is dispensed in Saudi Arabia

Ajovy is a subcutaneous injection self-administered at home with outpatient neurology or headache clinic review tracking monthly migraine days, acute medication use, HIT-6 or MIDAS disability scores, and hypersensitivity surveillance. The Saudi tertiary centres with dedicated neurology and headache service lines include King Faisal Specialist Hospital and Research Centre (KFSHRC) Department of Neurosciences in Riyadh, Jeddah, and Madinah, the flagship public specialty reference centre at kfshrc.edu.sa; King Fahad Medical City (KFMC) Neuroscience Centre in Riyadh under MOH at kfmc.med.sa; King Abdulaziz Medical City (KAMC, NGHA) Department of Neurology in Riyadh and Jeddah at ngha.med.sa; Prince Sultan Military Medical City Department of Neurology in Riyadh at psmmc.med.sa; and King Saud University Medical City Neurology Department in Riyadh at medicalcity.ksu.edu.sa. Among private tertiary, Dr. Sulaiman Al Habib Medical Group at hmg.com and Saudi German Hospital at saudigerman.com run neurology service lines including headache clinics. KFSHRC and KFMC are the most frequent dispensing nodes for CGRP-class biologics given their headache-clinic volume and biologic-dispensing pharmacy infrastructure.

What Ajovy costs in Saudi Arabia

The US wholesale acquisition cost for Ajovy is reported in manufacturer disclosures and the FDA Drugs@FDA channel at accessdata.fda.gov/scripts/cder/daf at approximately USD 615 to USD 720 per 225 mg single-dose pre-filled syringe or autoinjector, with annual drug-only spend at the monthly schedule of approximately USD 7,400 to USD 8,700 and equivalent annual cost on the quarterly schedule. Price snapshot: 2026-06-01. The Saudi Riyal is pegged to the US dollar at approximately 3.75 SAR to 1 USD per the Saudi Central Bank reference rate at sama.gov.sa. No current SFDA-published SAR maximum retail price for Ajovy is observed on the SFDA pricing channel at sfda.gov.sa as of 2026-06-01; do not estimate. Cost layers beyond the drug include refrigerated 2 to 8 degrees Celsius cold-chain logistics (Ajovy requires continuous temperature logging through the lane), SFDA permit and customs duties, dispensing fees, and the Reserve Meds concierge fee itemised separately on every firm quote. Local commercial stock when available is materially cheaper than US-sourced personal import.

Funding and access barriers for Ajovy in Saudi Arabia

CGRP migraine-preventive funding in Saudi Arabia is comparatively well-developed because migraine sits within the recognised burden the MOH tracks. For Saudi nationals, MOH-affiliated specialty centres (KFSHRC, KFMC, KAMC, Prince Sultan Military Medical City) provide CGRP-class biologics under public funding via NUPCO procurement at nupco.com, typically subject to documented inadequate response to first-line oral preventives. For private-sector employees, the Cooperative Health Insurance scheme regulated by the Council of Health Insurance at chi.gov.sa defines the Essential Benefits Package as the minimum floor; CGRP-class biologics for chronic migraine are typically included in mid-tier and higher corporate policies with prior authorisation and step-therapy from at least two oral preventives. Major insurers (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Al Rajhi Takaful, Walaa Cooperative, SAICO) cover Ajovy on most mid-tier corporate plans, often requiring documented chronic migraine (15 or more headache days per month for at least 3 months) and failure of two oral preventives before approval. Out-of-pocket exposure is most significant for plan exclusions and sub-limits on specialty biologics, or where the prescribed presentation is not locally stocked. KSrelief grants supplement coverage in defined humanitarian cases for non-citizens. The Saudi Headache Society is the practical referral and continuing-education anchor for headache-specialist neurologists.

Recent regulatory and access news for Ajovy

The European Medicines Agency expanded the Ajovy SmPC in 2025 covering paediatric chronic migraine in patients aged 12 years and older per the updated European Public Assessment Report at ema.europa.eu/medicines/human/EPAR/ajovy, broadening the in-label population available for Saudi clinical-justification documentation. The American Headache Society at americanheadachesociety.org and the European Headache Federation at ehf-org.org updated their consensus statements on CGRP-targeted therapy positioning in 2024 to 2025, reinforcing CGRP mAbs as first-line preventive options where access permits rather than requiring prior failure of multiple oral preventives. The SFDA continued its Drug Sector electronic-services modernisation per SFDA news at sfda.gov.sa/en/news, which incrementally compresses processing time for routine personal-import clearance permits. The SFDA Hajj 1446E (2025) annual clearance regulations at sfda.gov.sa Hajj 1446E govern Hajj-season medicines accompanying pilgrims; Ajovy patients travelling for Hajj follow this separate guideline. No drug-specific SFDA bulletin for Ajovy or fremanezumab over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Ajovy cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace SFDA, and we do not replace your dispensing pharmacy. For Ajovy specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Saudi Arabia, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Ajovy case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the SFDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Ajovy is administered as a 225 mg subcutaneous injection once monthly or as three consecutive 225 mg subcutaneous injections (675 mg) every 3 months via prefilled syringe or autoinjector; neurology follow-up tracks monthly migraine days, acute medication use, hypersensitivity signals, and MIDAS or HIT-6 disability scores.

Next step

If your Saudi physician has prescribed Ajovy and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Ajovy case Or message us on WhatsApp